c-MET (R1227K)
Sign in to save this workspaceMET · Variant type: point · HGVS: p.R1227K
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 91.3% | 8.7% | 88.97 |
| 2 | Canertinib | 48.2% | 51.8% | 96.49 |
| 3 | Abemaciclib | 40.9% | 59.1% | 91.48 |
| 4 | Repotrectinib | 22.2% | 77.8% | 84.21 |
| 5 | Sunitinib | 21.0% | 79.0% | 91.73 |
| 6 | Erlotinib | 15.7% | 84.3% | 99.75 |
| 7 | Vandetanib | 7.3% | 92.7% | 95.74 |
| 8 | Inavolisib | 4.9% | 95.1% | 100.00 |
| 9 | Acalabrutinib | 3.7% | 96.3% | 99.50 |
| 10 | Darovasertib | 2.5% | 97.5% | 96.99 |
| 11 | Cobimetinib | 1.6% | 98.4% | 100.00 |
| 12 | Remibrutinib | 1.3% | 98.7% | 99.50 |
| 13 | Palbociclib | 0.1% | 99.9% | 98.75 |
| 14 | Capivasertib | 0.0% | 100.0% | 96.48 |
| 15 | Quizartinib | 0.0% | 100.0% | 99.50 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 91.3% | — | — |
| Canertinib | 48.2% | — | — |
| Abemaciclib | 40.9% | — | — |
| Repotrectinib | 22.2% | — | — |
| Sunitinib | 21.0% | — | — |
| Erlotinib | 15.7% | — | — |
| Vandetanib | 7.3% | — | — |
| Inavolisib | 4.9% | — | — |
| Acalabrutinib | 3.7% | — | — |
| Darovasertib | 2.5% | — | — |
| Cobimetinib | 1.6% | — | — |
| Remibrutinib | 1.3% | — | — |
| Palbociclib | 0.1% | — | — |
| Capivasertib | 0.0% | — | — |
| Quizartinib | 0.0% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 20.0ms